PMC:7795856 / 234-688 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"19","span":{"begin":414,"end":417},"obj":"Gene"},{"id":"21","span":{"begin":421,"end":437},"obj":"Species"},{"id":"25","span":{"begin":356,"end":357},"obj":"Chemical"},{"id":"26","span":{"begin":373,"end":377},"obj":"Chemical"},{"id":"32","span":{"begin":93,"end":101},"obj":"Disease"},{"id":"33","span":{"begin":102,"end":112},"obj":"Disease"},{"id":"34","span":{"begin":117,"end":123},"obj":"Disease"}],"attributes":[{"id":"A19","pred":"tao:has_database_id","subj":"19","obj":"Gene:134864"},{"id":"A21","pred":"tao:has_database_id","subj":"21","obj":"Tax:562"},{"id":"A25","pred":"tao:has_database_id","subj":"25","obj":"MESH:D009584"},{"id":"A32","pred":"tao:has_database_id","subj":"32","obj":"MESH:C000657245"},{"id":"A33","pred":"tao:has_database_id","subj":"33","obj":"MESH:D007239"},{"id":"A34","pred":"tao:has_database_id","subj":"34","obj":"MESH:D009369"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"CV) infections and used as an immune enhancer, which also offers prospects in the context of COVID-19 infections and cancer. Manufacturing of this N-terminally acetylated 28-residue peptide is demanding, and its short plasma half-life limits in vivo efficacy and requires frequent dosing. Here, we combined the PASylation technology with enzymatic in situ N-acetylation by RimJ to produce a long-acting version of Tα1 in Escherichia coli at high yield. E"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T4","span":{"begin":117,"end":123},"obj":"Phenotype"}],"attributes":[{"id":"A4","pred":"hp_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"CV) infections and used as an immune enhancer, which also offers prospects in the context of COVID-19 infections and cancer. Manufacturing of this N-terminally acetylated 28-residue peptide is demanding, and its short plasma half-life limits in vivo efficacy and requires frequent dosing. Here, we combined the PASylation technology with enzymatic in situ N-acetylation by RimJ to produce a long-acting version of Tα1 in Escherichia coli at high yield. E"}

{"project":"LitCovid-sentences","denotations":[{"id":"T5","span":{"begin":125,"end":288},"obj":"Sentence"},{"id":"T6","span":{"begin":289,"end":452},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"CV) infections and used as an immune enhancer, which also offers prospects in the context of COVID-19 infections and cancer. Manufacturing of this N-terminally acetylated 28-residue peptide is demanding, and its short plasma half-life limits in vivo efficacy and requires frequent dosing. Here, we combined the PASylation technology with enzymatic in situ N-acetylation by RimJ to produce a long-acting version of Tα1 in Escherichia coli at high yield. E"}